.

Make Better Decisions

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chubb
Cerilliant
Johnson and Johnson
AstraZeneca
McKesson
Citi
Fish and Richardson
Cipla
Julphar
Baxter

Generated: December 15, 2017

DrugPatentWatch Database Preview

ADASUVE Drug Profile

« Back to Dashboard

Which patents cover Adasuve, and what generic alternatives are available?

Adasuve is a drug marketed by Galen Uk and is included in one NDA. There are eighteen patents protecting this drug.

This drug has two hundred and twenty-four patent family members in nineteen countries and six supplementary protection certificates in four countries.

The generic ingredient in ADASUVE is loxapine. There are eight drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the loxapine profile page.
Drug patent expirations by year for ADASUVE

Medical Subject Heading (MeSH) Categories for ADASUVE

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Galen Uk ADASUVEloxapinePOWDER;INHALATION022549-001Dec 21, 2012RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Galen Uk ADASUVEloxapinePOWDER;INHALATION022549-001Dec 21, 2012RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Galen Uk ADASUVEloxapinePOWDER;INHALATION022549-001Dec 21, 2012RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Galen Uk ADASUVEloxapinePOWDER;INHALATION022549-001Dec 21, 2012RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Galen Uk ADASUVEloxapinePOWDER;INHALATION022549-001Dec 21, 2012RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Galen Uk ADASUVEloxapinePOWDER;INHALATION022549-001Dec 21, 2012RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Galen Uk ADASUVEloxapinePOWDER;INHALATION022549-001Dec 21, 2012RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Galen Uk ADASUVEloxapinePOWDER;INHALATION022549-001Dec 21, 2012RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Galen Uk ADASUVEloxapinePOWDER;INHALATION022549-001Dec 21, 2012RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
Galen Uk ADASUVEloxapinePOWDER;INHALATION022549-001Dec 21, 2012RXYesYes► Subscribe► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: ADASUVE

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,814,954 Delivery of compounds for the treatment of Parkinsons through an inhalation route► Subscribe
6,805,853 Delivery of diazepam through an inhalation route► Subscribe
7,115,250Delivery of erectile dysfunction drugs through an inhalation route► Subscribe
7,470,421Delivery of diazepam through an inhalation route► Subscribe
6,740,308 Delivery of antihistamines through an inhalation route► Subscribe
6,855,310 Delivery of analgesics through an inhalation route► Subscribe
7,067,114Delivery of antihistamines through an inhalation route► Subscribe
7,022,312Delivery of antiemetics through an inhalation route► Subscribe
7,029,658Delivery of antidepressants through an inhalation route► Subscribe
6,797,259 Delivery of muscle relaxants through an inhalation route► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: ADASUVE

Country Document Number Estimated Expiration
Austria510174► Subscribe
Canada2641760► Subscribe
Canada2485721► Subscribe
Hungary0401008► Subscribe
European Patent Office1392261► Subscribe
World Intellectual Property Organization (WIPO)03026631► Subscribe
Austria462421► Subscribe
New Zealand529298► Subscribe
Japan2007516149► Subscribe
World Intellectual Property Organization (WIPO)03057188► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: ADASUVE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
00609Netherlands► SubscribePRODUCT NAME: LOXAPINE; REGISTRATION NO/DATE: EU/1/13/823/001-002 20130220
2013 00046Denmark► SubscribePRODUCT NAME: LOXAPIN; REG. NO/DATE: EU/1/13/823/001-002 20130220
0609Netherlands► SubscribePRODUCT NAME: LOXAPINE; REGISTRATION NO/DATE: EU/1/13/823/001-002 20130220
3Finland► Subscribe
2013 00046Denmark► SubscribePRODUCT NAME: LOXAPIN; REG. NO/DATE: EU/1/13/823/001-002 20130220
90040-2Sweden► SubscribePRODUCT NAME: LOXAPIN; REG. NO/DATE: EU/1/13/823/001 20130220
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Federal Trade Commission
Cantor Fitzgerald
AstraZeneca
Harvard Business School
Moodys
Johnson and Johnson
Boehringer Ingelheim
Chinese Patent Office
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot